ArticlePloS one2018
Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Pooled it
- Threshold effect of the METS-VF index on hyperuricemia in adults with hypertension: a cross-sectional study.BMC endocrine disorders · 2026Article
- The Association Between Serum Uric Acid Levels and the 10-Year Prospective Risk of Dyslipidemia: A Cohort Study From Healthy Heart Project (YHHP).Health science reports · 2025Article
- Association of obesity with hyperuricaemia among HIV-positive patients on antiretroviral therapy in South-Western Uganda.African journal of laboratory medicine · 2025Article
- Article
- Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.Clinical and molecular hepatology · 2025Review
- Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China.BMC endocrine disorders · 2024Article
- Serum uric acid and nonalcoholic fatty liver disease.Frontiers in endocrinology · 2024Review
- Trends in serum uric acid levels among Korean children and adolescents between 2016 and 2020: a nationwide study.European journal of pediatrics · 2023Article
- Cause-Specific Mortality in Patients With Gout in the US Veterans Health Administration: A Matched Cohort Study.Arthritis care & research · 2023Article
- Interaction of Harmful Alcohol Use and Tea Consumption on Hyperuricemia Among Han Residents Aged 30-79 in Chongqing, China.International journal of general medicine · 2023Article
- Changes in the prevalence of hyperuricemia in clients of health examination in Eastern China, 2009 to 2019.BMC endocrine disorders · 2022Article
- Prevalence of hyperuricemia in patients with severe obesity and the relationship between serum uric acid and severe obesity: A decade retrospective cross-section study in Chinese adults.Frontiers in public health · 2022Article
- Perirenal Fat Volume Is Positively Associated With Serum Uric Acid Levels in Chinese Adults.Frontiers in endocrinology · 2022Article
- Association between serum uric acid and obesity in Chinese adults: a 9-year longitudinal data analysis.BMJ open · 2021Article
- Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases.American journal of translational research · 2018Review
- Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease that is associated with high serum uric acid (SUA) levels, although the effects of high SUA levels on NAFLD remission remain unclear. In addition, it is unclear whether obesity and high SUA levels have a combined effect on NAFLD remission. This retrospective cohort study evaluated male employees of seven Chinese companies and investigated the association between high SUA levels and NAFLD remission, as well as the potential combined effect of high SUA levels and obesity on NAFLD remission. The study followed 826 men with NAFLD for 4 years, and the NAFLD remission rate was 23.2% (192/826). Comparing to obese and non-obese individuals with normouricemia, individuals with hyperuricemia had significant higher values for total cholesterol, triglycerides, creatinine, and aspartate transaminase (all P < 0.05). Among non-obese individuals, hyperuricemia was associated with a lower NAFLD remission rate, compared to normouricemia (P < 0.001). However, no significant difference was observed between hyperuricemia and normouricemia among obese subjects (P > 0.05). Similar results were observed in the multivariate cox proportional hazard regression analyses. Compared to the normouricemia subjects, individuals with hyperuricemia had a significant lower likelihood of NAFLD remission (RR = 0.535, 95% CI: 0.312-0.916); and obese subjects had a significant lower likelihood of NAFLD remission than the non-obese individuals (RR = 0.635, 95% CI: 0.439-0.918). In addition, the interaction between hyperuricemia and obesity had a statistically significant effect on NAFLD remission (P = 0.048). In conclusion, hyperuricemia and obesity may be involved in NAFLD development and remission, with similar pathogenic mechanisms. Further studies are needed to confirm our findings and determine how to improve these individuals' conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.